home · filing · 0001193125-26-390577
8-K filed September 14, 2026, 4:10 PM ET
ticker SION
CIK 0002036042
other material
confidence high
sentiment neutral
materiality 0.85
Sionna cuts workforce 46%, plans Phase 2a trial for SION-451+SION-2222
Sionna Therapeutics, Inc.
Board approved restructuring cutting ~46% of workforce, retaining core clinical capabilities for SION-451 and SION-2222.
Estimated restructuring charges of ~$6.4M, including $5.3M severance and $0.7M contract close-out for SION-719.
Chief Business Officer Caroline Stark Beer terminated without cause effective Sept 15, 2026; severance benefits approved.
Stock options repriced to closing price on Sept 17, 2026 for retained employees; original price reinstated if exercised before 18 months.
Plans to advance SION-451+SION-2222 into Phase 2a proof-of-concept trial initiating Q1 2027; cash runway extended into H2 2029.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2026-09-16
Filed September 14, 2026, 4:10 PM ET
Jennifer Fitzpatrick, the Company’s Chief Legal Officer, assumed the additional role of Head of Program Management
Effective 2026-09-16
Filed September 14, 2026, 4:10 PM ET
Elena Ridloff, the Company’s Chief Financial Officer, assumed the additional role of Chief Business Officer
Effective 2026-09-15
Filed September 14, 2026, 4:10 PM ET
the employment of Caroline Stark Beer, M.B.A., the Company’s Chief Business Officer, was terminated without cause, effective as of September 15, 2026
Effective 2026-09-16
Filed September 14, 2026, 4:10 PM ET
Charlotte McKee, the Company’s Chief Medical Officer, assumed the additional role of Head of Research and Development
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jennifer Fitzpatrick changed role as Head of Program Management at Sionna Therapeutics, Inc..
Action assumed
Role Head of Program Management
Exact text from the filing
Jennifer Fitzpatrick, the Company’s Chief Legal Officer, assumed the additional role of Head of Program Management
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Elena Ridloff changed role as Chief Business Officer at Sionna Therapeutics, Inc..
Action assumed
Role Chief Business Officer
Exact text from the filing
Elena Ridloff, the Company’s Chief Financial Officer, assumed the additional role of Chief Business Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Caroline Stark Beer was terminated as Chief Business Officer at Sionna Therapeutics, Inc..
Action terminated
Role Chief Business Officer
Exact text from the filing
the employment of Caroline Stark Beer, M.B.A., the Company’s Chief Business Officer, was terminated without cause, effective as of September 15, 2026
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Charlotte McKee changed role as Head of Research and Development at Sionna Therapeutics, Inc..
Action assumed
Role Head of Research and Development
Exact text from the filing
Charlotte McKee, the Company’s Chief Medical Officer, assumed the additional role of Head of Research and Development
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-26-390577
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.